Crossmark

Partial responders to intravenous corticosteroids at day 3 benefit from continued therapy in acute severe ulcerative colitis

Crossref DOI link: https://doi.org/10.1038/s41598-026-50171-4

Published Online: 2026-04-30

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Singh, Arshdeep https://orcid.org/0000-0001-7163-0454
Bhardwaj, Arshia https://orcid.org/0000-0001-5820-7758
Sharma, Riya https://orcid.org/0000-0002-0524-2696
Singh, Dharmatma https://orcid.org/0000-0001-7056-503X
Jain, Devanshi https://orcid.org/0000-0003-2345-4948
Bansal, Namita https://orcid.org/0000-0002-3601-4565
Sebastian, Shaji https://orcid.org/0000-0002-3670-6545
Peyrin-Biroulet, Laurent https://orcid.org/0000-0003-2536-6618
Midha, Vandana https://orcid.org/0000-0003-0192-3969
Sood, Ajit https://orcid.org/0000-0001-6961-6389
License Information

Text and Data Mining valid from 2026-04-30

Accepted Manuscript valid from 2026-04-30
More Information

Article History

Received: 28 September 2025

Accepted: 20 April 2026

First Online: 30 April 2026

Declarations

:

: Shaji Sebastian has received consulting fees from Celltrion, BMS Takeda, AbbVie, Merck, Ferring, Pharmacocosmos, Warner Chilcott, Janssen, Falk Pharma, Biohit, TriGenix, Celgene, Lilly and Tillots Pharma; has received payment or honoraria for lectures from AbbVie, Takeda, Celltrion, Pfizer, Biogen, AbbVie, Janssen, Merck, Warner Chilcott, Falk Pharma, Janssen and Lilly. Laurent Peyrin-Biroulet consults for Abbvie, Abivax, Adacyte, Alimentiv, Amgen, Applied Molecular Transport, Arena, Banook, Biogen, BMS, Celltrion, Connect Biopharm, Cytoki Pharma, Enthera, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead, Gossamer Bio, GSK, IAC Image Analysis, Index Pharmaceuticals, Inotrem, Janssen, Lilly, Medac, Mopac, Morphic, MSD, Nordic Pharma, Novartis, Oncodesign Precision Medicine, ONO Pharma, OSE Immunotherapeuthics, Pandion Therapeuthics, Par’ Immune, Pfizer, Prometheus, Protagonist, Roche, Samsung, Sandoz, Sanofi, Satisfay, Takeda, Telavant, Theravance, Thermo Fischer, Tigenix, Tillots, Viatris, Vectivbio, Ventyx, Ysopia and has received payment or honoraria for lectures from Abbvie, Amgen, Arena, Biogen, Celltrion, Ferring, Galapagos, Genentech, Gilead, Janssen, Lilly, Medac, MSD, Nordic Pharma, Pfizer, Sandoz, Takeda, Tillots, Viatris. Ajit Sood received honorarium for speaker events from Pfizer India and Takeda India. The remaining authors disclose no conflicts.

: The study was approved by institutional ethics committee (DMCH/R&D/2020/23).

Document is current

Any future updates will be listed below